Buy & Sell Dolby Laboratories, Inc. (DLB) – Dolby Laboratories, Inc. Price Today
Aura AI Summary
Key Stats
- $5.24BMarket Cap
- IndustrialsSector
- -16.81%3M Drawdown
- $4.69BEnterprise Value
- 2.55%Dividend Yield
- 68% Buy | 32% SellTrading Activity
- 92 daysTypical Hold Time
Dolby Laboratories, Inc. (DLB) is currently valued at a market capitalization of $5.24B, with an enterprise value of $4.69B. Over the past 52 weeks, Dolby Laboratories, Inc. has traded between a low of $54.29 and a high of $77.58, highlighting its annual price range. Over the past three months, Dolby Laboratories, Inc. has recorded a drawdown of -16.81%, reflecting recent price volatility. Dolby Laboratories, Inc. offers a dividend yield of 2.55%, with the most recent dividend of $0.36 paid on 12 May 26. On average, investors hold Dolby Laboratories, Inc. for approximately 92 days, indicating typical investor behavior on the platform.
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Most Recent News
Semiconductor recovery driven by supply constraints and pricing, not unit growth, led by memory chips for AI.
The semiconductor industry recovery is now led by memory chip pricing increases due to supply constraints rather than unit shipment growth. After a severe downturn in 2022, memory manufacturers cut capital expenditures and limited capacity expansion,...
Megan Holdings receives Nasdaq notice for falling below $1 minimum bid price, must regain compliance by Nov 2026.
Megan Holdings Limited announced it received a Nasdaq notification for not meeting the minimum bid price of $1 per share, with its shares trading below this threshold for 30 consecutive business days. The company has 180 days, until November 9, 2026,...
Absci insider buys shares amid financial challenges and positive clinical trial progress
A director at Absci purchased 37,453 shares, showing confidence despite the company's Q1 2026 revenue missing estimates by 90%. Absci reported a smaller-than-expected loss and progress in its ABS-201 clinical trial with positive safety data. The insi...